Our Pipeline at a glance

We have a proud legacy of turning breakthrough science into medicines and vaccines that save and improve lives around the world. We are focused on discovering new solutions for today and the future. We are grateful to the thousands of volunteers who participate in our clinical trials – making this all possible.

This table provides an overview of our late-stage clinical development programs and is updated quarterly. Updated November 3, 2022.

Download MSD Pipeline PDF

Our pipeline at a glance

80+

Programs in

Phase 2

25+

Programs in

Phase 3

10+

Programs

Under Review

Therapeutic area

Phase

Modality

Molecule Name Therapeutic Area
Potential Indications Status (i.e., Phase 2, 3, Under Review)
Modality

MK-4830

Colorectal cancer
Esophageal cancer
Melanoma
Non-small cell lung cancer
Ovarian
Renal cell cancer
Small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: MK-4830 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 4 (ILT-4) to its ligands.

MK-4830 is being developed in combination with KEYTRUDA.

MK-4830 is being developed under an agreement with Agenus Inc.

Modality: Monoclonal antibody

MK-4830

Mechanism of Action: MK-4830 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 4 (ILT-4) to its ligands.

MK-4830 is being developed in combination with KEYTRUDA.

MK-4830 is being developed under an agreement with Agenus Inc.

Oncology
Colorectal cancer
Esophageal cancer
Melanoma
Non-small cell lung cancer
Ovarian
Renal cell cancer
Small cell lung cancer
Monoclonal antibody

favezelimab
(MK-4280)

Non-small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules.

Favezelimab is being developed in combination with KEYTRUDA.

Modality: Monoclonal antibody

favezelimab

(MK-4280)

Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules.

Favezelimab is being developed in combination with KEYTRUDA.

Oncology
Non-small cell lung cancer
Monoclonal antibody

miransertib
(MK-7075)

Overgrowth syndrome
Therapeutic area: Oncology

Mechanism of Action: Miransertib is an investigational inhibitor of AKT (protein kinase B).

Miransertib was acquired as part of the acquisition of ArQule, Inc.

Modality: Small molecule

miransertib

(MK-7075)

Mechanism of Action: Miransertib is an investigational inhibitor of AKT (protein kinase B).

Miransertib was acquired as part of the acquisition of ArQule, Inc.

Oncology
Overgrowth syndrome
Small molecule

vibostolimab + pembrolizumab
(MK-7684A)

Non-small cell lung cancer
Small cell lung cancer
Biliary
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Esophageal cancer
Head and neck squamous cell cancer
Hematologic malignancies
Hepatocellular cancer
Prostate cancer
Therapeutic area: Oncology

Mechanism of Action: Vibostolimab is an investigational monoclonal antibody that binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits interactions with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Modality: Monoclonal antibody fixed-dose combination

vibostolimab + pembrolizumab

(MK-7684A)

Mechanism of Action: Vibostolimab is an investigational monoclonal antibody that binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits interactions with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Oncology
Non-small cell lung cancer
Small cell lung cancer
Biliary
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Esophageal cancer
Head and neck squamous cell cancer
Hematologic malignancies
Hepatocellular cancer
Prostate cancer
Monoclonal antibody fixed-dose combination

MK-3655

Nonalcoholic Steatohepatitis
Therapeutic area: Endocrinology

Mechanism of Action: MK-3655 is an investigational monoclonal antibody that activates the β-Klotho-Fibroblast Growth Factor Receptor (FGFR) 1c complex.

MK-3655 is being developed under an agreement with NGM Biopharmaceuticals.

Modality: Monoclonal antibody

MK-3655

Mechanism of Action: MK-3655 is an investigational monoclonal antibody that activates the β-Klotho-Fibroblast Growth Factor Receptor (FGFR) 1c complex.

MK-3655 is being developed under an agreement with NGM Biopharmaceuticals.

Endocrinology
Nonalcoholic Steatohepatitis
Monoclonal antibody

islatravir + lenacapavir
(MK-8591D)

HIV-1 infection
Therapeutic area: Antiviral

Mechanism of Action: Islatravir is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor.

MK-8591D is on FDA partial clinical hold.

Islatravir is being developed under an agreement with the Yamasa Corporation. The combination of islatravir and lenacapavir is being developed in a collaboration with Gilead Sciences, Inc.

Modality: Small molecule fixed-dose combination

islatravir + lenacapavir

(MK-8591D)

Mechanism of Action: Islatravir is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor.

MK-8591D is on FDA partial clinical hold.

Islatravir is being developed under an agreement with the Yamasa Corporation. The combination of islatravir and lenacapavir is being developed in a collaboration with Gilead Sciences, Inc.

Antiviral
HIV-1 infection
Small molecule fixed-dose combination

MK-2870

Neoplasm malignant
Therapeutic area: Oncology

Mechanism of Action: MK-2870 is an investigational antibody-drug conjugate that consists of an antibody-targeting trophoblast cell-surface antigen 2 (TROP2) linked to a belotecan-derived payload.

MK-2870 is being developed as monotherapy and/or in combination with KEYTRUDA.

MK-2870 is being developed in collaboration with Sichuan Kelun-Biotech.

Modality: Antibody-drug conjugate

MK-2870

Mechanism of Action: MK-2870 is an investigational antibody-drug conjugate that consists of an antibody-targeting trophoblast cell-surface antigen 2 (TROP2) linked to a belotecan-derived payload.

MK-2870 is being developed as monotherapy and/or in combination with KEYTRUDA.

MK-2870 is being developed in collaboration with Sichuan Kelun-Biotech.

Oncology
Neoplasm malignant
Antibody-drug conjugate

pembrolizumab subcutaneous
(MK-3475)

Non-small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Modality: Monoclonal antibody

pembrolizumab subcutaneous

(MK-3475)

Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Oncology
Non-small cell lung cancer
Monoclonal antibody

islatravir + doravirine
(MK-8591A)

Therapeutic area: Antiviral

Mechanism of Action: Islatravir is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1. Doravirine is a pyridinone non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

MK-8591A is on FDA partial clinical hold.

Islatravir is being developed under an agreement with the Yamasa Corporation.

Modality: Small molecule fixed-dose combination

islatravir + doravirine

(MK-8591A)

Mechanism of Action: Islatravir is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1. Doravirine is a pyridinone non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

MK-8591A is on FDA partial clinical hold.

Islatravir is being developed under an agreement with the Yamasa Corporation.

Antiviral
HIV-1 infection
Small molecule fixed-dose combination

LYNPARZA®
(MK-7339)

1L metastatic prostate cancer
Under Review (US, EU, JPN)

(PROpel; NCT03732820)

Non-small cell lung cancer
Small cell lung cancer
Advanced solid tumors
Therapeutic area: Oncology

Mechanism of Action: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.

LYNPARZA is being developed as a monotherapy and/or in combination with KEYTRUDA.

LYNPARZA is being developed in collaboration with AstraZeneca.

Modality: Small molecule

LYNPARZA®

(MK-7339)

Mechanism of Action: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.

LYNPARZA is being developed as a monotherapy and/or in combination with KEYTRUDA.

LYNPARZA is being developed in collaboration with AstraZeneca.

Oncology
1L metastatic prostate cancer

(PROpel; NCT03732820)

Under review (US, EU, JPN)
Non-small cell lung cancer
Small cell lung cancer
Advanced solid tumors
Small molecule

MK-1942

Treatment resistant depression
Therapeutic area: Neuroscience
Modality: Small molecule

MK-1942

Neuroscience
Treatment resistant depression
Small molecule

V184

Chikungunya virus
Therapeutic area: Vaccines

Description: V184 is an investigational live Schwarz-strain measles-vectored vaccine.

V184 was acquired as part of the acquisition of Themis.

Modality: Vaccine

V184

Description: V184 is an investigational live Schwarz-strain measles-vectored vaccine.

V184 was acquired as part of the acquisition of Themis.

Vaccines
Chikungunya virus
Vaccine

LENVIMA®
(MK-7902)

Colorectal cancer
Esophageal cancer
Gastric cancer
Head and neck squamous cell cancer
Melanoma
Non-small cell lung cancer
Biliary tract carcinoma
Glioblastoma
Pancreatic cancer
Prostate cancer
Small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.

LENVIMA is being developed in combination with KEYTRUDA.

LENVIMA is being developed in collaboration with Eisai.

Modality: Small molecule

LENVIMA®

(MK-7902)

Mechanism of Action: Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.

LENVIMA is being developed in combination with KEYTRUDA.

LENVIMA is being developed in collaboration with Eisai.

Oncology
Colorectal cancer
Esophageal cancer
Gastric cancer
Head and neck squamous cell cancer
Melanoma
Non-small cell lung cancer
Biliary tract carcinoma
Glioblastoma
Pancreatic cancer
Prostate cancer
Small cell lung cancer
Small molecule

MK-5684

Prostate cancer
Therapeutic area: Oncology

Mechanism of Action: MK-5684 is an investigational oral inhibitor of cytochrome P450 11A1.

MK-5684 is being developed in collaboration with Orion.

Modality: Small molecule

MK-5684

Mechanism of Action: MK-5684 is an investigational oral inhibitor of cytochrome P450 11A1.

MK-5684 is being developed in collaboration with Orion.

Oncology
Prostate cancer
Small molecule

V181

Dengue fever virus
Therapeutic area: Vaccines

Description: V181 is an investigational quadrivalent dengue vaccine.

Modality: Vaccine

V181

Description: V181 is an investigational quadrivalent dengue vaccine.

Vaccines
Dengue fever virus
Vaccine

MK-5475

Pulmonary arterial hypertension
Therapeutic area: Cardiovascular

Mechanism of Action: MK-5475 is an investigational stimulator of soluble Guanylate Cyclase (sGC).

Modality: Small molecule

MK-5475

Mechanism of Action: MK-5475 is an investigational stimulator of soluble Guanylate Cyclase (sGC).

Cardiovascular
Pulmonary arterial hypertension
Small molecule

MK-0482

Non-small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: MK-0482 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 3 (ILT3) to its ligands.

MK-0482 is being developed in combination with KEYTRUDA.

Modality: Monoclonal antibody

MK-0482

Mechanism of Action: MK-0482 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 3 (ILT3) to its ligands.

MK-0482 is being developed in combination with KEYTRUDA.

Oncology
Non-small cell lung cancer
Monoclonal antibody

V116

Pneumococcal, adult
Therapeutic area: Vaccines

Description: V116 is an investigational 21 valent pneumococcal conjugate vaccine.

Modality: Vaccine

V116

Description: V116 is an investigational 21 valent pneumococcal conjugate vaccine.

Vaccines
Pneumococcal, adult
Vaccine

MK-8189

Schizophrenia
Therapeutic area: Neuroscience

Mechanism of Action: MK-8189 is an investigational inhibitor of phosphodiesterase 10A (PDE10A).

MK-8189 is being developed under an agreement with Royalty Pharma. Phase 2b development costs are being co-funded.

Modality: Small molecule

MK-8189

Mechanism of Action: MK-8189 is an investigational inhibitor of phosphodiesterase 10A (PDE10A).

MK-8189 is being developed under an agreement with Royalty Pharma. Phase 2b development costs are being co-funded.

Neuroscience
Schizophrenia
Small molecule

clesrovimab
(MK-1654)

Respiratory syncytial virus
Therapeutic area: Respiratory

Mechanism of Action: Clesrovimab is an investigational respiratory syncytial virus (RSV) fusion (F) glycoprotein neutralizing monoclonal antibody.

Modality: Monoclonal antibody

clesrovimab

(MK-1654)

Mechanism of Action: Clesrovimab is an investigational respiratory syncytial virus (RSV) fusion (F) glycoprotein neutralizing monoclonal antibody.

Respiratory
Respiratory syncytial virus
Monoclonal antibody

gefapixant
(MK-7264)

Cough
Under Review (US*, EU)
Therapeutic area: Respiratory

Mechanism of Action: Gefapixant is an investigational P2X3 receptor antagonist.

*In response to the Complete Response Letter received Jan 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023.

Gefapixant was acquired as part of the acquisition of Afferent Pharmaceuticals.

Modality: Small molecule

gefapixant

(MK-7264)

Mechanism of Action: Gefapixant is an investigational P2X3 receptor antagonist.

*In response to the Complete Response Letter received Jan 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023.

Gefapixant was acquired as part of the acquisition of Afferent Pharmaceuticals.

Respiratory
Cough
Under review (US*, EU)
Small molecule

vibostolimab
(MK-7684)

Therapeutic area: Oncology

Mechanism of Action: Vibostolimab is an investigational monoclonal antibody that binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits interactions with its ligands.

Vibostolimab is being developed in combination with KEYTRUDA.

Modality: Monoclonal antibody

vibostolimab

(MK-7684)

Mechanism of Action: Vibostolimab is an investigational monoclonal antibody that binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits interactions with its ligands.

Vibostolimab is being developed in combination with KEYTRUDA.

Oncology
Melanoma
Monoclonal antibody

VAXNEUVANCE™
(V114)

Pneumococcal Infection for pediatric use
Under Review (JPN)
Therapeutic area: Vaccines

Description: V114 is a 15 valent pneumococcal conjugate vaccine.

Modality: Vaccine

VAXNEUVANCE™

(V114)

Description: V114 is a 15 valent pneumococcal conjugate vaccine.

Vaccines
Pneumococcal Infection for pediatric use
Under review (JPN)
Vaccine

LAGEVRIO™
(MK-4482)

COVID-19
Under Review (EU)
COVID-19
Therapeutic area: Antiviral

Mechanism of Action: Molnupiravir is an investigational antiviral ribonucleoside prodrug of N-hydroxycytidine (NHC). NHC triphosphate is incorporated into viral RNA by viral RNA polymerase and results in an accumulation of errors in the viral genome leading to inhibition of replication.

LAGEVRIO is being developed under an agreement with Ridgeback Biotherapeutics LP. LAGEVRIO is available in the U.S. under Emergency Use Authorization.

Modality: Small molecule

LAGEVRIO™

(MK-4482)

Mechanism of Action: Molnupiravir is an investigational antiviral ribonucleoside prodrug of N-hydroxycytidine (NHC). NHC triphosphate is incorporated into viral RNA by viral RNA polymerase and results in an accumulation of errors in the viral genome leading to inhibition of replication.

LAGEVRIO is being developed under an agreement with Ridgeback Biotherapeutics LP. LAGEVRIO is available in the U.S. under Emergency Use Authorization.

Antiviral
COVID-19
Under review (EU)
(US)
Small molecule

nemtabrutinib
(MK-1026)

Hematological malignancies
Therapeutic area: Oncology

Mechanism of Action: Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of oncogenic B-cell receptor signaling with activity against wild-type BTK and BTK pathway mutants.

Nemtabrutinib was acquired as part of the acquisition of ArQule, Inc.

Modality: Small molecule

nemtabrutinib

(MK-1026)

Mechanism of Action: Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of oncogenic B-cell receptor signaling with activity against wild-type BTK and BTK pathway mutants.

Nemtabrutinib was acquired as part of the acquisition of ArQule, Inc.

Oncology
Hematological malignancies
Small molecule

ladiratuzumab vedotin
(MK-6440)

Breast cancer
Esophageal cancer
Gastric cancer
Head and neck squamous cell cancer
Melanoma
Non-small cell lung cancer
Prostate
Small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Ladiratuzumab vedotin is an investigational humanized antibody targeting the zinc transporter LIV-1 conjugated with a microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a proteolytically cleavable linker.

Ladiratuzumab vedotin is being developed as a monotherapy and/or in combination with KEYTRUDA.

Ladiratuzumab vedotin is being developed under an agreement with Seagen.

Modality: Antibody-drug conjugate

ladiratuzumab vedotin

(MK-6440)

Mechanism of Action: Ladiratuzumab vedotin is an investigational humanized antibody targeting the zinc transporter LIV-1 conjugated with a microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a proteolytically cleavable linker.

Ladiratuzumab vedotin is being developed as a monotherapy and/or in combination with KEYTRUDA.

Ladiratuzumab vedotin is being developed under an agreement with Seagen.

Oncology
Breast cancer
Esophageal cancer
Gastric cancer
Head and neck squamous cell cancer
Melanoma
Non-small cell lung cancer
Prostate
Small cell lung cancer
Antibody-drug conjugate

sotatercept
(MK-7962)

Pulmonary arterial hypertension
Pulmonary hypertension due to left heart disease
Therapeutic area: Cardiovascular

Mechanism of Action: Sotatercept is an investigational soluble activin receptor type IIA fusion protein that binds to activins and growth differentiation factors.

Sotatercept was acquired as part of the acquisition of Acceleron.

Modality: Therapeutic protein

sotatercept

(MK-7962)

Mechanism of Action: Sotatercept is an investigational soluble activin receptor type IIA fusion protein that binds to activins and growth differentiation factors.

Sotatercept was acquired as part of the acquisition of Acceleron.

Cardiovascular
Pulmonary arterial hypertension
Pulmonary hypertension due to left heart disease
Therapeutic protein

V940

Melanoma
Therapeutic area: Oncology

Mechanism of Action: V940 is an investigational mRNA-based personalized cancer vaccine targeting tumor associated antigens expressed by a patient’s cancer cells.

V940 is being developed in combination with KEYTRUDA.

V940 is being developed in collaboration with Moderna.

Modality: Vaccine

V940

Mechanism of Action: V940 is an investigational mRNA-based personalized cancer vaccine targeting tumor associated antigens expressed by a patient’s cancer cells.

V940 is being developed in combination with KEYTRUDA.

V940 is being developed in collaboration with Moderna.

Oncology
Melanoma
Vaccine

quavonlimab
(MK-1308)

Non-small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands.

Quavonlimab is being developed in combination with KEYTRUDA.

Quavonlimab is being developed under an agreement with Akeso, Inc.

Modality: Monoclonal antibody

quavonlimab

(MK-1308)

Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands.

Quavonlimab is being developed in combination with KEYTRUDA.

Quavonlimab is being developed under an agreement with Akeso, Inc.

Oncology
Non-small cell lung cancer
Monoclonal antibody

MK-0616

Hypercholesterolemia
Therapeutic area: Cardiovascular

Mechanism of Action: MK-0616 is an investigational inhibitor of Proprotein convertase subtilisin/kexin type 9 (PCSK9).

MK-0616 is being developed under an agreement with UCB Pharmaceuticals.

Modality: Peptide

MK-0616

Mechanism of Action: MK-0616 is an investigational inhibitor of Proprotein convertase subtilisin/kexin type 9 (PCSK9).

MK-0616 is being developed under an agreement with UCB Pharmaceuticals.

Cardiovascular
Hypercholesterolemia
Peptide

islatravir + MK-8507
(MK-8591B)

HIV-1 infection
Therapeutic area: Antiviral

Mechanism of Action: Islatravir is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1. MK-8507 is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

MK-8591B is on FDA clinical hold.

Islatravir is being developed under an agreement with the Yamasa Corporation.

Modality: Small molecule fixed-dose combination

islatravir + MK-8507

(MK-8591B)

Mechanism of Action: Islatravir is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1. MK-8507 is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

MK-8591B is on FDA clinical hold.

Islatravir is being developed under an agreement with the Yamasa Corporation.

Antiviral
HIV-1 infection
Small molecule fixed-dose combination

TUKYSA®
(MK-7119)

Breast cancer
Colorectal cancer
Advanced solid tumors
Biliary tract carcinoma
Bladder
Cervical
Endometrial
Non-small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Tucatinib is a tyrosine kinase inhibitor of HER2.

TUKYSA is being developed in collaboration with Seagen.

Modality: Small molecule

TUKYSA®

(MK-7119)

Mechanism of Action: Tucatinib is a tyrosine kinase inhibitor of HER2.

TUKYSA is being developed in collaboration with Seagen.

Oncology
Breast cancer
Colorectal cancer
Advanced solid tumors
Biliary tract carcinoma
Bladder
Cervical
Endometrial
Gastric
Non-small cell lung cancer
Small molecule

quavonlimab + pembrolizumab
(MK-1308A)

Renal cell carcinoma
Colorectal cancer
Hepatocellular carcinoma
Melanoma
Small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Quavonlimab is being developed under an agreement with Akeso, Inc.

Modality: Monoclonal antibody fixed-dose combination

quavonlimab + pembrolizumab

(MK-1308A)

Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Quavonlimab is being developed under an agreement with Akeso, Inc.

Oncology
Renal cell carcinoma
Colorectal cancer
Hepatocellular carcinoma
Melanoma
Small cell lung cancer
Monoclonal antibody fixed-dose combination

MK-2060

Thrombosis
Therapeutic area: Cardiovascular

Mechanism of Action: MK-2060 is an investigational monoclonal antibody that inhibits the activation of Factor XI and activity of Factor XIA.

MK-2060 is being developed under an agreement with Adimab.

Modality: Monoclonal antibody

MK-2060

Mechanism of Action: MK-2060 is an investigational monoclonal antibody that inhibits the activation of Factor XI and activity of Factor XIA.

MK-2060 is being developed under an agreement with Adimab.

Cardiovascular
Thrombosis
Monoclonal antibody

efinopegdutide
(MK-6024)

Nonalcoholic Steatohepatitis
Therapeutic area: Endocrinology

Mechanism of Action: Efinopegdutide is an investigational dual GLP-1/glucagon receptor agonist.

Efinopegdutide is being developed under an agreement with Hanmi Pharmaceutical.

Modality: Peptide

efinopegdutide

(MK-6024)

Mechanism of Action: Efinopegdutide is an investigational dual GLP-1/glucagon receptor agonist.

Efinopegdutide is being developed under an agreement with Hanmi Pharmaceutical.

Endocrinology
Nonalcoholic Steatohepatitis
Peptide

KEYTRUDA®
(MK-3475) **

2L hepatocellular cancer
Under Review (US)

(KN-394; NCT03062358)

Non-small cell lung cancer (Adjuvant Setting)
Under Review (US, EU)

(KN-091; NCT02504372)

Biliary tract carcinoma
Cutaneous squamous cell carcinoma (EU)
Gastric cancer (EU)
Hepatocellular carcinoma (EU)
Mesothelioma
Ovarian cancer
Prostate cancer
Small cell lung cancer
Advanced solid tumors
Therapeutic area: Oncology

Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

**Select KEYTRUDA clinical trials are shown.

Modality: Monoclonal antibody

KEYTRUDA®

(MK-3475) **

Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

**Select KEYTRUDA clinical trials are shown.

Oncology
2L hepatocellular cancer

(KN-394; NCT03062358)

Under review (US)
Non-small cell lung cancer (Adjuvant Setting)

(KN-091; NCT02504372)

Under review (US, EU)
Biliary tract carcinoma
Cutaneous squamous cell carcinoma (EU)
Gastric cancer (EU)
Hepatocellular carcinoma (EU)
Mesothelioma
Ovarian cancer
Prostate cancer
Small cell lung cancer
Advanced solid tumors
Monoclonal antibody

zilovertamab vedotin
(MK-2140)

Breast cancer
Gastric cancer
Hematological malignancies
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Therapeutic area: Oncology

Mechanism of Action: Zilovertamab vedotin is an investigational antibody-drug conjugate that consists of a ROR1-targeting antibody linked to monomethyl auristatin E (MMAE)-containing payload.

Zilovertamab vedotin was acquired as part of the acquisition of VelosBio.

Modality: Antibody-drug conjugate

zilovertamab vedotin

(MK-2140)

Mechanism of Action: Zilovertamab vedotin is an investigational antibody-drug conjugate that consists of a ROR1-targeting antibody linked to monomethyl auristatin E (MMAE)-containing payload.

Zilovertamab vedotin was acquired as part of the acquisition of VelosBio.

Oncology
Breast cancer
Gastric cancer
Hematological malignancies
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Antibody-drug conjugate

boserolimab
(MK-5890)

Non-small cell lung cancer
Small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Boserolimab is an investigational monoclonal antibody that binds and activates CD27.

Boserolimab is being developed in combination with KEYTRUDA.

Boserolimab is being developed under an agreement with Chinook Therapeutics.

Modality: Monoclonal antibody

boserolimab

(MK-5890)

Mechanism of Action: Boserolimab is an investigational monoclonal antibody that binds and activates CD27.

Boserolimab is being developed in combination with KEYTRUDA.

Boserolimab is being developed under an agreement with Chinook Therapeutics.

Oncology
Non-small cell lung cancer
Small cell lung cancer
Monoclonal antibody

favezelimab + pembrolizumab
(MK-4280A)

Colorectal cancer
Hematological malignancies
Esophageal cancer
Renal cell carcinoma
Small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Modality: Monoclonal antibody fixed-dose combination

favezelimab + pembrolizumab

(MK-4280A)

Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Oncology
Colorectal cancer
Hematological malignancies
Esophageal cancer
Renal cell carcinoma
Small cell lung cancer
Monoclonal antibody fixed-dose combination

WELIREG™
(MK-6482)

Renal cell carcinoma
Biliary tract carcinoma
Colorectal cancer
Endometrial cancer
Esophageal cancer
Hepatocellular carcinoma
Pancreatic
Rare cancers
Certain VHL-associated tumors (EU)
Therapeutic area: Oncology

Mechanism of Action: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). Belzutifan binds to HIF-2α, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2α-HIF-1β interaction, leading to reduced transcription and expression of HIF-2α target genes.

WELIREG is being developed as a monotherapy and/or in combination with KEYTRUDA.

WELIREG was acquired as part of the acquisition of Peloton Therapeutics, Inc.

Modality: Small molecule

WELIREG™

(MK-6482)

Mechanism of Action: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). Belzutifan binds to HIF-2α, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2α-HIF-1β interaction, leading to reduced transcription and expression of HIF-2α target genes.

WELIREG is being developed as a monotherapy and/or in combination with KEYTRUDA.

WELIREG was acquired as part of the acquisition of Peloton Therapeutics, Inc.

Oncology
Renal cell carcinoma
Biliary tract carcinoma
Colorectal cancer
Endometrial cancer
Esophageal cancer
Hepatocellular carcinoma
Pancreatic
Rare cancers
Certain VHL-associated tumors (EU)
Small molecule

What do the phases of clinical trials mean?

Phase 1

Phase 1 clinical trials test the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital. The goals are to determine:

  • If the medicine or vaccine is safe
  • If there are any side effects
  • How the medicine is broken down by and discharged from the body
  • How much medicine is needed and how often
  • For a vaccine, researchers see if it causes the desired response from the body’s immune system

Phase 1 trials can take from six months to one year to complete.

 


Phase 2

Phase 2 clinical trials test the vaccine or medicine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy. The goals of this phase are to determine:

  • How well the medicine or vaccine works
  • If the medicine or vaccine is safe
  • If there are any side effects
  • How much of the medicine or vaccine is needed and how often

Phase 2 trials can take from six months to one year or more to complete.


Phase 3

Phase 3 clinical trials can test the medicine or vaccine in 1,000 to 5,000 patient volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices. Researchers closely monitor patients at regular intervals to:

  • Confirm that the medication or vaccine is effective
  • Identify and monitor side effects
  • Compare the medicine or vaccine to commonly used treatments

Phase 3 trials can take from one to four years to complete, depending on the disease, length of study and number of volunteers.


Under review

The application has been submitted to the regulatory authorities for review.


No Duty to Update

The information contained in this chart was current as of November 3, 2022. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after November 3, 2022.

The chart reflects the company research pipeline as of November 3, 2022.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.